Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment

Cancer Biology and Therapy

Volumn 7, Issue 7, 2008, Pages 1006-1013

  Eichhorn, M E ^a   Strieth, S ^a   Luedemann, S ^a   Kleespies, A ^a   Noth U ^b   Passon, A ^a   Brix, G ^c   Jauch, K W ^a   Bruns, C J ^a   Dellian, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c BUNDESAMT FÜR STRAHLENSCHUTZ   (Germany)

Author keywords

Angiogenesis; Anti angiogenic tumor therapy; MRI; Normalization; SU5416; VEGF

Indexed keywords

SEMAXANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL DIAMETER; CANCER GROWTH; CANCER TISSUE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ERYTHROCYTE; FLUORESCENCE MICROSCOPY; HAMSTER; MALE; MELANOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN TENSION; PHOTOCHEMICAL QUENCHING; SHORT COURSE THERAPY; SKINFOLD; SUBCUTANEOUS TISSUE TUMOR; TISSUE OXYGENATION; TREATMENT DURATION; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

EID: 47949096436     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.7.5997     Document Type: Article

References (38)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-8.
3. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987-9.
4. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
5. Webb T. Vascular normalization: study examines how antiangiogenesis therapies work. J Natl Cancer Inst 2005; 97:336-7.
6. Batchelor TT, Sorensen AG, di TE, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY and Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95.
7. Fukumura D and Jain RK. Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc Res 2007; 74:72-84.
8. Brazelle WD, Shi W and Siemann DW. VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65:836-41.
9. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P and Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105:15-24.
10. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK and Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001; 61:39-44.
11. Nieder C, Wiedenmann N, Andratschke N and Molls M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006; 32:348-64.
12. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ and Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64:3731-6.
13. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di TE, Munn LL and Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1 and matrix metalloproteinases. Cancer Cell 2004; 6:553-63.
14. Lin MI and Sessa WC. Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell 2004; 6:529-31.
15. Weiss N, Delius M, Gambihler S, Dirschedl P, Goetz A and Brendel W. Influence of the shock wave application mode on the growth of A-Mel 3 and SSK2 tumors in vivo. Ultrasound Med Biol 1990; 16:595-605.
16. Haase A. Snapshot FLASH MRI. Applications to T1, T2 and chemical-shift imaging. Magn Reson Med 1990; 13:77-89.
17. Deichmann R. and Haase A. Quantification of T1 values by Snaptshot-FLASH NMR imaging. J Magn Reson 1992; 96:608-612
18. Pahernik S, Griebel J, Botzlar A, Gneiting T, Brandl M, Dellian M and Goetz AE. Quantitative imaging of tumour blood flow by contrast-enhanced magnetic resonance imaging. Br J Cancer 2001; 85:1655-63.
19. Brix G, Kiessling F, Lucht R, Darai S, Wasser K, Delorme S and Griebel J. Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. Magn Reson Med 2004; 52:420-9.
20. Eichhorn ME, Becker S, Strieth S, Werner A, Sauer B, Teifel M, Ruhstorfer H, Michaelis U, Griebel J, Brix G, Jauch KW and Dellian M. Paclitaxel Encapsulated in Cationic Lipid Complexes (MBT-0206) Impairs Functional Tumor Vascular Properties as Detected by Dynamic Contrast Enhanced Magnetic Resonance Imaging. Cancer Biol Ther 2006; 5:89-96.
21. Asaishi K, Endrich B, Götz A and Messmer K. Quantitative analysis of microvascular structure and function in the amelanotic melanoma A-Mel-3. Cancer Res 1981; 41:1898-904.
22. Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U and Dellian M. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 2004; 110:117-24.
23. Baker M and Wayland H. On-line volume flow rate and velocity profile measurement for blood in microvessels. Microvasc Res 1974; 7:131-43.
24. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997; 3:177-82.
25. Lo LW, Koch CJ and Wilson DF. Calibration of oxygen-dependent quenching of the phosphorescence of Pd-meso-tetra (4-carboxyphenyl) porphine: a phosphor with general application for measuring oxygen concentration in biological systems. Anal Biochem 1996; 236:153-60.
26. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Hirth KP, Ullrich A and Fong TA. Inhibition of tumor growth, angiogenesis and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1999; 1:31-41.
27. Pahernik S, Harris AG, Schmitt-Sody M, Krasnici S, Goetz AE, Dellian M and Messmer K. Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study. Br J Cancer 2002; 86:1622-7.
28. Dvorak HF, Nagy JA and Dvorak AM. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 1991; 3:77-85.
29. Folberg R, Hendrix MJ and Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000; 156:361-81.
30. Konerding MA, Miodonski AJ and Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc 1995; 9:1233-43.
31. Munn LL. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 2003; 8:396-403.
32. Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K and Dellian M. Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 2002; 86:788-95.
33. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP and McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res 1999; 59:99-106.
34. Eichhorn ME, Kleespies A, Angele MK, Jauch KW and Bruns CJ. Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg 2007; 392:371-9.
35. Cheung AM, Brown AS, Cucevic V, Roy M, Needles A, Yang V, Hicklin DJ, Kerbel RS and Foster FS. Detecting Vascular Changes in Tumour Xenografts Using Micro-Ultrasound and Micro-CT Following Treatment with VEGFR-2 Blocking Antibodies. Ultrasound Med Biol 2007; 33:1259-68.
36. Jain RK, Tong RT and Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007; 67:2729-35.
37. Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A and Leenders WP. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008; 7:71-8.
38. Taguchi E, Nakamura K, Miura T, Shibuya M and Isoe T. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci 2008; 99:623-30.